Parvacure Medical

Parvacure Medical is a clinical-stage biotechnology company based in Israel that focuses on the development of oncolytic virus therapies for high-unmet-need cancers. The company's lead therapeutic candidate is H-1PV, a naturally occurring rodent parvovirus that selectively replicates within and destroys human cancer cells. This oncolytic agent is particularly notable for its ability to cross the blood-brain barrier, making it a promising candidate for treating primary and metastatic brain tumors like glioblastoma. Beyond direct cell lysis, H-1PV therapy is designed to trigger a systemic anti-tumor immune response, potentially addressing metastatic disease. Parvacure is currently advancing clinical trials for both glioblastoma and pancreatic ductal adenocarcinoma. The company leverages decades of research originally conducted at the German Cancer Research Center (DKFZ) to bring these viral therapies to market.